Halia Therapeutics yaratidza dhata nhasi pachirongwa chayo cheNLRP3 inhibitor pamusangano wanhasi wechigumi Wepagore Neurodegenerative Drug Development Summit.
Dr. David J. Bearss, Mutungamiriri, uye Mutungamiriri Mukuru weHalia Therapeutics, vakaratidza migumisiro inoratidza kuti kushandisa allosteric targeting approach kune chikamu cheNLRP3 complex kwakagonesa kugadzirwa kwekirasi itsva yemishonga inotarisa zvose NLRP3 activation uye basa. Aya madiki mamorekuru ekurapa ane mukana wekunongedza akawanda systemic kuzvimba uye neurological chirwere zviratidzo. Mharidzo yaDr. Bearss yakanga ine musoro unoti, “Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease.” Musangano uyu wakaitirwa kuBoston Park Plaza, Boston, Massachusetts, kubva Kurume 28 kusvika 30, 2022.
"Iyo data uye zano rakaratidzwa nhasi rinomiririra paradigm nyowani yekunangana neNLRP3. Tinofara zvikuru nekuwana allosteric modulators eNLRP3 inflammasome, uye tiri kufambira mberi zvirongwa zvakawanda takananga kukiriniki tichishandisa nzira yekunangana nayo iyi,” akadaro Jared Bearss, COO weHalia. "Kugona kuvharisa musangano uye kusimudzira kuparara kweNLRP3 inflammasome complex inomiririra mukana wakakosha wekupa marapirwo matsva kuvarwere vane chirwere chetsinga uye chinopisa."
ZVOKUBVA MUNYAYA INO:
- Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target both NLRP3 activation and function.
- “The ability to both inhibit the assembly and promote the disassembly of the NLRP3 inflammasome complex represents a significant opportunity to provide new therapeutics for patients suffering from neurological and inflammatory diseases.
- Kana iwe uine rumwe ruzivo rwezvinogoneka kuwedzera, kubvunzurudza kunoratidzwa pa eTurboNews, uye zvakaonekwa nevanopfuura Mamirioni maviri vanoverenga, vanoteerera, uye vanotiona mumitauro 2 tinya pano.
